Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu, 610041, Sichuan, China.
Division of Infectious Diseases, State Key Laboratory of Biotherapy, Guoxuexiang 37, Chengdu, 610041, Sichuan, China.
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1761-1766. doi: 10.1007/s10096-021-04198-2. Epub 2021 Feb 17.
KPC-12 is a variant of KPC-2 with a L169M substitution in the Ω loop, but its resistance spectrum was not reported. bla was cloned, and KPC-12 exhibited significantly decreased activities against imipenem, meropenem, aztreonam, and piperacillin-tazobactam with ≥4-fold lower MICs than KPC-2. However, unlike the L169P substitution in KPC-35, activities against ceftazidime and ceftazidime-avibactam of KPC-12 were unaltered. This highlights that different substitutions at the same position of carbapenemases may have varied impact on the activity.
KPC-12 是 KPC-2 的一种变体,在 Ω 环中有一个 L169M 取代,但它的耐药谱尚未报道。bla 被克隆,KPC-12 对亚胺培南、美罗培南、氨曲南和哌拉西林-他唑巴坦的活性显著降低,MIC 至少低 4 倍,而 KPC-2 则相反。然而,与 KPC-35 的 L169P 取代不同,KPC-12 对头孢他啶和头孢他啶-阿维巴坦的活性没有改变。这表明,在同一位置的碳青霉烯酶的不同取代可能对活性有不同的影响。